Loading…
Chinese maker of ultrasound imaging systems and endoscopes sold to hospitals worldwide.
Chinese maker of ultrasound imaging systems and endoscopes sold to hospitals worldwide.
Sells equipment to hospitals mainly through distributors, and in China many sales go through public-hospital tenders, so government health spending and procurement drive results. Probes and endoscope accessories add repeat sales after the machine is sold. Export sales are a major part of the business.
In one line: A Chinese Mindray for ultrasound/endoscopy imaging.
Moat: narrow (brand, distribution). Export distribution network and brand recognition built over two decades in imaging.
Headquarters: Shenzhen, Guangdong, China · Founded: 1994 · Employees: 3,133
Size Sonoscape Medical (300633.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.42B, the 1714th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥22.32 on 6 Nov 2026.
Performance Over six months the shares fell 8.3%, against -6.7% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 17.5% over the last twelve months (peer median +7.3%); the operating margin is 4.1% (peer median 15.3%).
Valuation It trades at 36.8× forward earnings against a peer median of 21.8× (6th most expensive of 18).
Capital Return on invested capital runs 0.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.44B | CN¥2.29B | CN¥2.00B | CN¥2.10B | CN¥1.75B |
| Revenue growth | — | +15% | -5% | +20% | — |
| Gross profit | CN¥1.53B | CN¥1.33B | CN¥1.21B | CN¥1.41B | CN¥1.14B |
| EBITDA | n/a | CN¥149M | CN¥116M | CN¥429M | CN¥311M |
| Net income | CN¥175M | CN¥197M | CN¥142M | CN¥454M | CN¥370M |
| Free cash flow | -CN¥42.4M | -CN¥185M | CN¥105M | CN¥317M | CN¥296M |
| Capital expenditure | CN¥154M | CN¥142M | CN¥207M | CN¥177M | CN¥190M |
| Total debt | CN¥364M | CN¥318M | CN¥355M | CN¥72.4M | CN¥221M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sonoscape Medical 300633.SZ | $1.42B | -8% | +18% | 4% | 36.8× | n/a |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | $33.4B | +9% | +5% | 28% | 27.1× | 0.9% |
| GE HealthCare GEHC | $37.2B | +30% | +7% | 14% | 15.4× | 4.3% |
| SamsungElec 005930.KS | $886B | -14% | +88% | 46% | 4.0× | -7.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300633.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.0% | +2.8% | 3rd highest of 21 |
| 6-month return | -8.3% | -6.7% | 10th lowest of 21 |
| Distance from 52-week high | -35.2% | -29.1% | 8th lowest of 21 |
| Revenue growth (TTM) | +17.5% | +7.3% | 6th highest of 20 |
| Operating margin | 4.1% | 15.3% | 7th lowest of 20 |
| Forward P/E | 36.8× | 21.8× | 6th most expensive of 18 |
| ROIC minus cost of capital | +0.9 pp | +1.4 pp | 10th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 36.8× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 19% | 16.3× | 2.2% | +19.7% |
| Ovctek China 300595.SZ | China | $1.42B | -26% | 0% | 28% | 20.8× | 9.9% | +16.5% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 21.8× | 9.8% | +7.7% |
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% | +23.6% |
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 1% | 39.0× | n/a | n/a |
| Beijing Balance Medical Technology 688198.SS | China | $1.47B | -26% | +10% | 28% | 46.6× | 22.6% | +27.6% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | 2% | 130.1× | n/a | n/a |
| CONMED CNMD | United States | $1.53B | +40% | +2% | 2% | 11.1× | 32.4% | +9.8% |
| NovoCure NVCR | United States | $1.55B | -26% | +13% | -17% | n/a | n/a | n/a |
| NIPRO 8086.T | Japan | $1.55B | -9% | +3% | 6% | 14.9× | n/a | n/a |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 7.7× | 22.3% | -6.0% |
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | n/a | n/a | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% | +40.3% |
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% | +18.3% |
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 18% | 45.8× | n/a | n/a |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 17.2× | 3.1% | +23.4% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -74% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 46% | 12.1× | -8.7% | +34.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% | -3.5% |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 17.6× | -2.1% | +3.3% |